Skip to main content
. 2019 Sep 9;3:35. doi: 10.21037/med.2019.08.02

Table 1. Clinical activity of ICIs in relapsed TETs.

Parameter NCT02364076 (Pembrolizumab) NCT02607631 (Pembrolizumab) NCT01772004 (Avelumab)
Thymic carcinoma Thymoma Thymic carcinoma Thymoma
Number of patients 40 7 26 7
Response rate (%) 22.5 28.6 19.2 28.5
Median PFS (months) 4.2 6.1 6.1 NA
Median OS (months) 24.9 NR 14.5 NA

TET, thymic epithelial tumor; PFS, progression-free survival; OS, overall survival; NR, not reached; NA, not available; ICIs, immune checkpoint inhibitors.